Surveillance of the prevalence, antibiotic susceptibility, and genotypic characterization of invasive candidiasis in a teaching hospital in China between 2006 to 2011

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Li, Fang ^a   Wu, Lin ^a   Cao, Bin ^a   Zhang, Yuyu ^a   Li, Xiaoli ^a   Liu, Yingmei ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Antifungal susceptibility; Epidemiology; Genotyping; Invasive Candida

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; FUNGAL DNA; ITRACONAZOLE; MICROSATELLITE DNA; RIBOSOME DNA; VORICONAZOLE;

AGED; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CHINA; CULTURE MEDIUM; DISEASE SURVEILLANCE; FEMALE; FUNGAL STRAIN; FUNGUS CULTURE; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; GENOTYPE; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PROTEIN DOMAIN; SINGLE STRAND CONFORMATION POLYMORPHISM; TEACHING HOSPITAL;

AGED; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, INVASIVE; CHINA; COHORT STUDIES; CROSS INFECTION; FEMALE; HOSPITALS, TEACHING; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PREVALENCE;

EID: 84880936372     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-353     Document Type: Article

References (31)

1. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007, 20:133-163. 10.1128/CMR.00029-06, 1797637, 17223626.
2. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008, 29:996-1011. 10.1086/591861, 18947320.
3. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535. 10.1086/596757, 19191635.
4. Yenigün Koçak B, Kuloǧlu F, Doǧan Çelik A, Akata F. Evaluation of epidemiological characteristics and risk factors of candidemia in adult patients in a tertiary-care hospital. Mikrobiyol Bul 2011, 45:489-503.
5. Arnold HM, Micek ST, Shorr AF, Zilberberg MD, Labelle AJ, Kothari S. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy 2010, 30:361-368. 10.1592/phco.30.4.361, 20334456.
6. Chen LY, Liao SY, Kuo SC, Chen SJ, Chen YY, Wang FD. Changes in the incidence of candidaemia during 2000-2008 in a tertiary medical centre in northern Taiwan. J Hosp Infect 2011, 78:50-53. 10.1016/j.jhin.2010.12.007, 21316800.
7. Chow JK, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y, Lichtenberg D. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis 2008, 46:1206-1213. 10.1086/529435, 18444857.
8. Sipsas NV, Kontoyiannis DP. Invasive fungal infections in patients with cancer in the Intensive Care Unit. Int J Antimicrob Agents 2012, 39:464-471. 10.1016/j.ijantimicag.2011.11.017, 22337064.
9. Panackal AA, Gribskov JL, Staab JF, Kirby KA, Rinaldi M, Marr KA. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol 2006, 44:1740-1743. 10.1128/JCM.44.5.1740-1743.2006, 1479212, 16672401.
10. Spreghini E, Orlando F, Sanguinetti M, Posteraro B, Giannini D, Manso E. Comparative Effects of Micafungin, Caspofungin, and Anidulafungin against a Difficult-To-Treat Fungal Opportunistic Pathogen, Candida glabrata. Antimicrob Agents Chemother 2012, 56:1215-1222. 10.1128/AAC.05872-11, 3294882, 22203604.
11. Kurtzman CP, Robnett CJ. Identification of clinically important ascomycetous yeasts based on nucleotide divergence in the 5′ end of the large-subunit (26S) ribosomal DNA gene. J Clin Microbiol 1997, 35:1216-1223. 232732, 9114410.
12. Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of clinical and laboratory standards institute broth microdilution methods, 2010 to 2012. J Clin Microbiol 2012, 50:2846-2856. 10.1128/JCM.00937-12, 3421803, 22740712.
13. Li J, Bai FY. Single-strand conformation polymorphism of microsatellite for rapid strain typing of Candida albicans. Med Mycol 2007, 45(7):629-635. 10.1080/13693780701530950, 17885945.
14. Sampaio P, Gusmao L, Correia A, Alves C, Rodrigues AG, Pina-Vaz C. New microsatellite multiplex PCR for Candida albicans strain typing reveals microevolutionary changes. J Clin Microbiol 2005, 43:3869-3876. 10.1128/JCM.43.8.3869-3876.2005, 1233915, 16081924.
15. Garner JS, Jarvis WR, Emori TG. CDC definations for nosocomial infections. Am J Infect Control 1988, 16:128-140. 10.1016/0196-6553(88)90053-3, 2841893.
16. Pereira GH, Muller PR, Szeszs MW, Levin AS, Melhem MS. Five-year evaluation of bloodstream yeast infections in a tertiary hospital: the predominance of non-C. albicans Candida species. Med Mycol 2010, 48:839-842. 10.3109/13693780903580121, 20163281.
17. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302:2323-2329. 10.1001/jama.2009.1754, 19952319.
18. Lockhart SR, Iqbal N, Ahlquist AM, Farley MM, Harrison LH, Bolden CB. Species identification and antifungal susceptibility of candida bloodstream isolates from population-based surveillance in two US cities from 2008-2011. J Clin Microbiol 2012, 50:3435-3442. 10.1128/JCM.01283-12, 3486211, 22875889.
19. Wang H, Xiao M, Chen SC, Kong F, Sun ZY, Liao K, Lu J, Shao HF, Yan Y, Fan H, Hu ZD, Chu YZ, Hu TS, Ni YX, Zou GL, Xu YC. In Vitro Susceptibilities of Yeast Species to Fluconazole and Voriconazole as Determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study. J Clin Microbiol 2012, 50:3952-3959. 10.1128/JCM.01130-12, 3502960, 23035204.
20. Pfaller MA, Diekema D, Gibbs D, Newell V, Ellis D, Tullio V. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010, 48:1366-1377. 10.1128/JCM.02117-09, 2849609, 20164282.
21. Kao AS, Brandt ME, Pruitt WR, Conn LA, Perkins BA, Stephens DS. The epidemiology of candidemia in two United States cities:results of a population-based active surveillance. Clin Infect Dis 1999, 29:1164-1170. 10.1086/313450, 10524958.
22. Lyon GM, Karatela S, Sunay S, Adiri Y. Antifungal susceptibility testing of Candida isolates from the Candida surveillance study. J Clin Microbiol 2010, 48:1270-1275. 10.1128/JCM.02363-09, 2849617, 20129963.
23. Mean M, Marchetti O, Calandra T. Bench-to-bedside review: Candida infections in the intensive care unit. Crit Care 2008, 12:204. 10.1186/cc6212, 2374590, 18279532.
24. Wu JQ, Zhu LP, Ou XT, Xu B, Hu XP, Wang X, Weng XH. Epidemiology and risk factors for non-Candida albicans candidemia in non-neutropenic patients at a Chinese teaching hospital. Med Mycol 2011, 49:552-555.
25. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Monzon A, Buitrago MJ, Rodriguez-Tudela JL. Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. Antimicrob Agents Chemother 2009, 53:2192-2195. 10.1128/AAC.01543-08, 2681500, 19223630.
26. Manzoni P, Leonessa M, Galletto P, Latino MA, Arisio R, Maule M. Routine use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively fluconazole-resistant Candida subspecies. Pediatr Infect Dis J 2008, 27:731-737. 10.1097/INF.0b013e318170bb0c, 18600191.
27. Liu Y, Kang Y, Yokoyama K, Gonoi T, Mikami Y. Molecular differentiation and antifungal susceptibility of Candida albicans isolated from patients with respiratory infections in Guiyang Medical College Hospital, China. Nihon Ishinkin Gakkai Zasshi 2009, 50:175-178. 10.3314/jjmm.50.175, 19654451.
28. Seneviratne CJ, Wong SS, Yuen KY, Meurman JH, Parnanen P, Vaara M. Antifungal susceptibility and virulence attributes of bloodstream isolates of Candida from Hong Kong and Finland. Mycopathologia 2011, 172:389-395. 10.1007/s11046-011-9444-4, 21744043.
29. Tortorano AM, Prigitano A, Dho G, Grancini A, Passera M. Antifungal susceptibility profiles of Candida isolates from a prospective survey of invasive fungal infections in Italian intensive care units. J Med Microbiol 2012, 61:389-393. 10.1099/jmm.0.037895-0, 22096131.
30. Chen TC, Chen YH, Chen YC, Lu PL. Fluconazole exposure rather than clonal spreading is correlated with the emergence of Candida glabrata with cross-resistance to triazole antifungal agents. Kaohsiung J Med Sci 2012, 28:306-315. 10.1016/j.kjms.2011.11.011, 22632885.
31. Hattori H, Iwata T, Nakagawa Y, Kawamoto F, Tomita Y, Kikuchi A. Genotype analysis of Candida albicans isolates obtained from different body locations of patients with superficial candidiasis using PCRs targeting 25S rDNA and ALT repeat sequences of the RPS. J Dermatol Sci 2006, 42:31-46. 10.1016/j.jdermsci.2005.12.003, 16414246.